FDA Update.


Treanda (bendamustine HCL): Recall – Particulate Matter in Vial

ISSUE: Cephalon, Inc. notified healthcare professionals of a recall of Treanda (bendamustine HCL) for Injection 25mg/8mL, lot TB30111, expiration date 12/2012. This product lot is being recalled due to the presence of particulate matter found in a single vial, which has been identified as glass fragments. Potential adverse events after intravenous administration of solutions containing particulates may present as an emboli and result in disruption of blood flow causing tissue/organ damage, especially in vulnerable patients such as those undergoing surgery, immunosuppressed individuals, and the elderly, as well as patients with micro or macrovasular disease, such as cardiac and renal disease, who may be more at risk since their vasculature and end organs are already compromised.

The affected Treanda lot is packaged in 8 mL vials and was distributed to wholesalers and distributors nationwide between March 22, 2011 and October 5, 2011.

BACKGROUND: Treanda (bendamustine HCL) for Injection 25mg/8mL is indicated for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab-containing regimen.

RECOMMENDATION: Recipients of the subject lot have been previously notified of this recall via overnight notification on 11/18/11. Wholesalers, retailers, hospitals and health care professionals who have lot TB30111 in their possession are instructed to immediately cease using the product and immediately quarantine product for return.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

 

 

Vitaflo USA Renastart: Recall – Possible Health Risk Due To Incorrectly Labeled Cans

ISSUE: Vitaflo USA has announced a voluntary recall of Renastart 14.11 oz (400g) cans, Batch Number 12832, because some of the product shipped throughout the United States during the period December 29, 2011 through January 26, 2012 was incorrectly labeled. Some immediate consequences of using the incorrectly labeled product may result in high potassium blood levels (hyperkalemia) or high sodium levels in the blood (hypernatremia). All other Vitaflo products, including Renastart cans in batches other than 12832 and Renastart packed in sachets, are not affected.

BACKGROUND: Renastart is a powdered medical food used in the dietary management of pediatric renal disease, for patients one year and older. Renastart 14.11oz (400g) product in cans is sold only in the United States. Following a customer complaint regarding the way the product was dissolving, Vitaflo determined that a small number of cans of a different product may have been wrongly labeled as Renastart.

RECOMMENDATION: Vitaflo USA is urging anyone who has any Renastart 14.11 oz (400g) cans Batch Number 12832 to immediately stop using the product and to contact Vitaflo to arrange return of the product, at Vitaflo’s expense.  All patients who have consumed any Renastart from this batch should contact their health care professional immediately to determine next steps, including nutritional management alternatives.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

 

 

Lo/Ovral-28 (Norgestrel/EthinylEstradiol) Tablets: Recall – Possibility of Inexact Tablet Counts or Out of Sequence Tablets

ISSUE: Pfizer Inc. notified healthcare professionals and consumers that it recalled 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market. An investigation by Pfizer found that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence. As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy.

BACKGROUND: These products are oral contraceptives indicated for the prevention of pregnancy. These products are packaged in blister packs containing 21 tablets of active ingredients and seven tablets of inert ingredients. Correct dosing of this product is important in avoiding the associated risks of an unplanned pregnancy.

RECOMMENDATION: Patients who have the affected product should notify their physician and return the product to the pharmacy. See the Press Release for a list of affected lot numbers.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

 

Be One in a Million this American Heart Month.


Cardiovascular disease is the leading cause of death in the United States; one in every three deaths is from heart disease and stroke, equal to 2,200 deaths per day.

“Heart disease takes the lives of far too many people in this country, depriving their families and communities of someone they love and care for—a father, a mother, a wife, a friend, a neighbor, a spouse. With more than 2 million heart attacks and strokes a year, and 800,000 deaths, just about all of us have been touched by someone who has had heart disease, heart attack, or a stroke.”
– Department of Health and Human Services Secretary Kathleen Sebelius

February is American Heart Month, and unfortunately, most of us know someone who has had heart disease or stroke. Cardiovascular disease is the leading cause of death in the United States; one in every three deaths is from heart disease and stroke, equal to 2,200 deaths per day. These conditions are also leading causes of disability preventing people from working and enjoying family activities. Cardiovascular disease is also very expensive—together heart disease and stroke hospitalizations in 2010 cost the nation more than $444 billion in health care expenses and lost productivity. However, we can fight back against heart disease and stroke. CDC and other parts of the US government have launched Million Hearts™, to prevent the nation’s leading killers and empowering everyone to make heart-healthy choices.

What is Million Hearts™?

Additional Million Hearts™ partners:

  • Federal Partners
    • Agency for Healthcare Research and Quality
    • Health Resources and Services Administration
    • HHS Office of the Secretary
    • Indian Health Service
    • National Institutes of Health
    • Office of the National Coordinator for Health IT
    • Substance Abuse and Mental Health Services Administration
  • Private-Sector Partners
    • American Heart Association
    • Walgreens
    • National Alliance of State Pharmacy Associations
    • Alliance for Patient Medication Safety
    • National Community Pharmacists Association
    • American Pharmacists Association
    • American Pharmacists Association Foundation
    • YMCA
    • America’s Health Insurance Plans-Aetna, UnitedHealthCare, WellPoint, Cigna
    • American Medical Association
    •  American Nurses Association
    • Kaiser Permanente

Launched in September 2011 by the Department of Health and Human Services (HHS), Million Hearts™ is a national initiative that aims to prevent 1 million heart attacks and strokes in the U.S. over the next five years. This public-private partnership, co-led by CDC and the Center for Medicare and Medicaid Services (CMS) is integrating and amplifying a range of existing heart disease and stroke prevention programs, policies, and activities.

Goals of Million Hearts™

The Million Hearts™ Initiative seeks to prevent 1 million heart attacks and strokes by the end of 2016 by:

  • Empowering Americans to make healthy choices such as avoiding tobacco use and reducing the amount of sodium and trans fat they eat. These changes will reduce the number of people who need medical treatment for high blood pressure or cholesterol—and ultimately prevent heart attacks and strokes.
  • Improving care for people who do need treatment by encouraging a focus on the “ABCS”—Aspirin for people at risk, Blood pressure control, Cholesterol management, and Smoking cessation—four steps to address the major risk factors for cardiovascular disease and help to prevent heart attacks and strokes.

Million Hearts™ Support

Million Hearts™ has the support of multiple federal agencies and key private organizations, including the American Heart Association, the American Pharmacists’ Association, the YMCA, Walgreens, and UnitedHealthCare. Over the next five years, Million Hearts™ is pursuing commitments and participation from many more partners in health care, public health, industry, and government. These partnerships will help Million Hearts™ leverage and advance existing investments in cardiovascular disease prevention.

What Million Hearts™ Means to You

Heart disease and stroke affects all of our lives, but we can all play a role in ending it. Prevention starts with everyone. Protect yourself and your loved ones from heart disease and stroke by understanding the risks and taking these steps.

  • Drive the initiative by challenging your family and friends to take the Million Hearts™ pledge at http://www.millionhearts.hhs.gov.
  • Get up and get active by being physically active for at least 30 minutes on most days of the week.
  • Know your ABCS:
    • Ask your doctor if you should take an Aspirin every day.
    • Find out if you have high Blood pressure or Cholesterol, and if you do, get effective treatment.
    • If you Smoke, get help to quit.
  • Make your calories count by eating a heart-healthy diet high in fresh fruits and vegetables and low in sodium and trans fat.
  • Take control of your heart health by following your doctor’s prescription instructions.

Source:CDC

Vaccinate Against Flu: It’s Not Too Late!


Have you taken the steps to prevent flu this season? If not, it isn’t too late. Flu vaccination is the first and most important thing you can do to protect against flu.

Don’t let influenza (the flu) catch YOU by surprise this season. Be prepared; get vaccinated today.

After a busy holiday season, you might be reluctant to add one more thing to your to-do list. But it’s worth it.

“Getting the flu vaccine is simple, and it’s the most important thing you can do to protect yourself and your family from the flu,” says Dr. Anne Schuchat, Assistant Surgeon General of the U.S. Public Health Service and Director of CDC’s National Center for Immunization and Respiratory Diseases.

If you haven’t gotten your flu vaccine yet, there is still time to protect yourself and your family by getting vaccinated. Flu season is just beginning in the United States and the season may not peak until February or March. It’s also possible that we could continue to see flu in the United States until May.

Get a Flu Vaccine Every Flu Season

The best way to protect against the flu is to get a flu vaccine every flu season. The flu is a contagious respiratory disease that can lead to serious complications, hospitalization, or even death. Anyone can get the flu, and getting a flu vaccine is the single best way to protect yourself and your family. Even healthy people can get very sick from the flu and spread it to friends and loved ones. Everyone 6 months of age and older is recommended to get vaccinated against the flu every year.

Flu activity is unpredictable but often peaks in January or February.  And although there are many different flu viruses, the yearly flu vaccine protects against the three viruses that research suggests will be most common that flu season.

So what are your options? There are 3 different types of flu shots. The regular flu shot is recommended for almost everyone, 6 months of age and older. The high-dose flu shot is available for adults 65 years of age and older, and the intradermal flu shot uses a very small needle, and is available for adults 18-64 years of age. If you are afraid of getting the flu shot, consider FluMist®. It’s a nasal spray vaccine and is safe and effective for healthy people, 2 through 49 years of age who are not pregnant.

Important reminder for parents and caregivers: Many children getting vaccinated against the flu for the first time will need 2 doses of flu vaccine to be fully protected. If a child has not received his/her first dose, get them vaccinated now. For those who have been vaccinated with one dose, parents should check with the child’s doctor to see if a second dose is needed for full protection.

Who Is at Risk?

Everyone is at risk for getting the flu. For millions of people each year, the flu can bring a fever, cough, sore throat, runny or stuffy nose, muscle aches, fatigue, and miserable days spent in bed. However, you may not realize that the flu also leads to more than 200,000 flu-related hospitalizations per year. The flu also can be deadly. Between 1976 and 2007, CDC estimates that annual flu-associated deaths in the United States ranged from a low of about 3,000 people to a high of about 49,000 people.

Anyone can get the flu, but some people are at greater risk for serious flu-related complications, like pneumonia. For those at greater risk for complications, getting the flu vaccine is especially important. Some of the groups at greater risk include:

It also is important to get vaccinated if you care for anyone in these high risk groups, including babies younger than 6 months because they are too young to get vaccinated themselves.

Get Vaccinated – It’s Not Too Late

You and your family can still benefit from a flu vaccine. Make a commitment to your health and to your family’s health by getting your flu vaccine today. Flu vaccines are offered in many doctors’ offices, clinics, grocery stores, pharmacies, local health departments, and possibly even your child’s school or your workplace. So even if you don’t have a regular doctor, you can get a flu vaccine at many other locations. Use the Flu Vaccine Finder to find the nearest location with available flu vaccine.

So don’t let the flu catch YOU by surprise this season; be prepared and get vaccinated today if you haven’t already–it’s not too late!

For more information about the seriousness of the flu and the benefits of the flu vaccine, talk to your family’s doctor or visit www.cdc.gov/flu

Source:CDC

 

 

 

 

 

 

Success Stories in Environmental Health.


Read about how the National Center for Environmental Health (NCEH) and the Agency for Toxic Substances and Disease Registry (ATSDR) protect and promote environmental health across the United States.

  • Your drinking water well is contaminated by benzene from industrial activities near your home.
  • Your seven-year-old child suffers from severe asthma, and you don’t know how to help him.
  • Your child’s school is contaminated by mercury found in a science lab.
  • You are suffering from depression following a man-made disaster near your community

These are actual examples of the many ways your environment can affect your health.

Your environment is everything around you—the air you breathe, the water you drink, the places where your food is grown or prepared, your workplace, and your home.  When your environment is safe and healthy, you are more likely to stay healthy. But when your environment exposes you to dangerous events or harmful amounts of toxic substances, your health can be affected. In fact, 25% of all diseases worldwide are caused by something harmful in the environment.

The National Center for Environmental Health (NCEH), part of the Centers for Disease Control and Prevention (CDC), and the Agency for Toxic Substances and Disease Registry (ATSDR), a sister agency to the CDC, are committed to keeping people safe from environmental hazards. Each agency works to

  • promote healthy environments,
  • respond to natural and man-made disasters,
  • support public health workers,
  • educate communities,
  • promote environmental justice, and
  • provide scientific knowledge.

Although NCEH and ATSDR staff frequently work together on common issues, each has a different focus and different types of activities.

NCEH focuses on the broader health issues caused by hazards in the environment. The center conducts research; tracks health problems related to the environment; and supports local, state, tribal and national health agencies. NCEH also combats illnesses associated with environmental hazards such as air pollution, mold, lead, contaminated food and water, and animals that carry disease. In addition, the center provides aid to create healthy homes and to ensure that cruise ships are safe for passengers and crew.

ATSDR focuses on protecting the public from exposures to toxic substances. The agency investigates hazards in communities by collecting and analyzing information on environmental exposures and health. It provides recommendations to communities and industries to limit or prevent exposure to hazardous substances. ATSDR also provides scientific expertise on toxic substances and their effects on health and collects information about people who have the same health condition or disease.

Whatever the activity, NCEH and ATSDR staff members focus on making a real difference in people’s lives. “Sharing Our Stories” describes our successes in protecting and improving people’s health across the United States. For example, you can read about how ATSDR began a national investigation into the cause of a disease cluster in Pennsylvania or how NCEH’s lead poisoning prevention program has protected thousands of children from the mental health effects of lead exposure. Click on the links below to read these stories and more accounts of the work of NCEH and ATSDR. And keep checking back for more news about how these agencies protect people from harm in the environment.

Source:CDC

 

 

Yoga decreased insomnia in postmenopausal women.


Yoga may reduce insomnia and menopausal symptoms and improve quality of life in postmenopausal women with insomnia, according to researchers in Brazil.

“The practice of yoga has been proven to have positive effects on reducing insomnia,” the researchers wrote. “Studies have also shown its effects on reducing climacteric symptoms. To date, however, no studies that evaluate the effects of yoga on postmenopausal women with a diagnosis of insomnia in a randomized clinical trial have been conducted.”

This randomized trial included 44 postmenopausal women aged 50 to 65 years who were not undergoing hormone therapy. The women had an apnea-hypopnea index of less than 15 and a diagnosis of insomnia. Women with uncontrolled clinical illnesses such as systemic arterial hypertension, diabetes or cancer were excluded.

The women were randomly assigned to one of three groups: control, passive stretching and yoga. The passive stretching group had two 1-hour sessions per week of passive stretching. The yoga group had two 1-hour sessions a week of yoga with a yoga teacher. The women completed questionnaires before the intervention and after the 4-month study to evaluate quality of life, anxiety and depression, climacteric symptoms, insomnia severity, daytime sleepiness and stress.

At the end of the study, the participants in the yoga group had significantly lower post-treatment scores for climacteric symptoms and insomnia severity and higher scores for quality of life and resistance phase of stress vs. the control group. The insomnia severity was also lower in the yoga group compared with the passive stretching group.

Source:Endocrine Today.

 

Combination linagliptin plus metformin receives FDA approval.


Boehringer Ingelheim and Eli Lilly recently announced that the FDA has approved its combination linagliptin/metformin hydrochloride tablets for treatment of adults with type 2 diabetes.

The linagliptin/metformin combination (Jentadueto) is a single tablet that is meant to be taken twice daily as an adjunct to diet and exercise in patients with type 2 diabetes when treatment with both linagliptin (Tradjenta, Boehringer Ingelheim) and metformin is appropriate. According to a press release by the manufacturers, the drug demonstrated placebo-corrected reductions in HbA1c of up to 1.7%, and can be used alone or combined with a sulfonylurea. The medication, however, is not intended for use in patients with type 1 diabetes or diabetic ketoacidosis and has not been studied in combination with insulin. Additionally, Jentadueto contains a boxed warning regarding a risk for lactic acidosis.

“Most people with type 2 diabetes require more than one medication to help lower their blood sugar due to the complex nature of type 2 diabetes,” Lance Sloan, MD, of the Texas Institute for Kidney and Endocrine Disorders, said in the press release. “The approval of Jentadueto is exciting because it combines two diabetes medications in a single tablet, making it a good option for people who need an additional medication and for whom both linagliptin and metformin is appropriate.”

The agency based approval on clinical trials evaluating linagliptin and metformin as separate tablets. Bioequivalence of Jentadueto was demonstrated with co-administered linagliptin and metformin tablets in healthy participants. In the trials, patients treated with Jentadueto experienced nasopharyngitis and diarrhea more commonly than those receiving placebo. Researchers also found that hypoglycemia was more commonly reported in patients treated with Jentadueto combined with a sulfonylurea vs. those treated with a combination of placebo, sulfonylurea and metformin (22.9% vs. 14.8%). Further, pancreatitis was reported more often in patients assigned to linagliptin (one per 538 person-years vs. zero in 433 person-years for comparator).

“We are proud to bring this important new single-tablet treatment option, taken twice daily, to the millions of people currently living with type 2 diabetes,” said David Pass, PharmD, vice president of cardiovascular and metabolic disorders marketing at Boehringer Ingelheim. “We are hopeful that Jentadueto, the newest member of the growing family of products from the Boehringer Ingelheim and Lilly diabetes alliance, may help people living with blood sugar levels that are not controlled.”

Source:Endocrine Today.

FDA approves exenatide extended-release for injectable suspension in type 2 diabetes.


Amylin Pharmaceuticals, Inc. and Alkermes PLC announced that the FDA has approved exenatide extended-release for injectable suspension, a once-weekly treatment for patients with type 2 diabetes. The treatment will be available nationwide beginning in February.

The glucagon-like peptide-1 receptor agonist is indicated as an adjunct to diet and exercise for improved glycemic control,

Approval is based on data from DURATION-5, a head-to-head study that demonstrated that after 24 weeks of treatment, patients experienced a statistically significant reduction in HbA1c of 1.6 percentage points. The study compared once-weekly treatment with exenatide extended-release for injectable suspension (Bydureon) with twice-daily treatment with exenatide injection (Byetta).

Both treatment groups achieved statistically significant weight loss at the study’s end, with an average loss of 5.1 lb for patients taking Bydureon and 3 lb for those taking Byetta. Nausea was the most commonly reported side effect in both groups, but occurred less often in the Bydureon group (14% vs. 35% for Byetta).

The once-weekly treatment is approved with a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the risk for acute pancreatitis and the potential risk for medullary thyroid carcinoma. Amylin has established a communication plan for health care professionals to help minimize these risks as part of the REMS. Additionally, the company will complete post-marketing requirements to further assess the effect of Bydureon on medullary thyroid cancer and cardiovascular disease, according to the press release.

In November 2011, Amylin and Eli Lilly and Company announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the two companies, according to a press release. At this time, full responsibility for the worldwide development and commercialization of exenatide was granted to Amylin.

“With Bydureon, US physicians and patients can now choose a therapy that offers continuous blood sugar control in just one dose per week,” John Buse, MD, PhD, professor of medicine, director of the Diabetes Care Center and chief of the division of endocrinology at the University of North Carolina School of Medicine in Chapel Hill, said in a press release. “New treatment options are essential for the millions of adults with type 2 diabetes who continue to struggle to achieve optimal blood sugar control.”

Source:Endocrine Today.

Study shows how swiftly infectious viruses evolve.


When viruses face an obstacle to infecting the cells they normally infect, how long does it take for them to evolve to successfully invade them again? A new study has a frightening answer: just a little more than two weeks.

The study raises more questions and fears about the evolution of viruses just a month after the government asked two scientific journals to halt publication of details about bird flu viruses that were cultivated in the lab to be easily transmitted among humans.

In this latest study, published Thursday in the journal Science, a team of scientists at Michigan State University studied a virus that is harmless to humans, called lambda, which normally infects the bacterium, Escherichia coli.

Normally, lambda gets into E. coli by latching onto a molecule on the bacterium’s surface. From there, it injects its won genes and proteins in the microbe.

Justin Meyer, a graduate student in the biology laboratory of Richard Lenski, created a version of E. coli that had almost none of the molecules lambda needs to infect the bacterium, so that very few of the lambda cells could get in.

But within 15 days, the lambda cells had evolved to use a different molecule, called OmpF, to invade E. coli. As the New York Times reports, “Lambda viruses had never been reported to use OmpF before. Mr. Meyer was surprised not just by how fast the change happened, but that it happened at all. “I thought it would be a wild goose chase,” he said. ”

To see if the rapid evolution was just an aberration, he did the same test with 96 lines. In 24 of the lines, not only did the viruses all mutated to use OmpF, but they all did so in a series of four mutations. On top of that, in almost all of them, the four mutations were identical.

The Times says,

Some critics have argued that full-blown evolution would not be able to mimic the highly artificial Dutch experiment. The chances that a single virus would acquire so many mutations at once are certainly small. In the case of lambda viruses, Mr. Meyer estimates the chance of all four mutations arising at once is roughly one in a thousand trillion trillion.

Additionally, the virus did not succeed in developing the proper mutation in the majority of cases. Why? As MSNBC reports, the bacteria also mutated, producing a protein on the inner membrane that prevented the virus from entering the cell.

The study shows the potential for us to predict the evolution of viruses and bacteria, plus gives us new insight into how viruses that attack humans, such as the deadly bird flu virus, might evolve.

Source:IBM Smart planet.

 

Gigantic Radio Telescope to Search for First Stars and Galaxies.


The array could be the most complex and versatile radio telescope ever attempted, with the capacity to sweep the entire northern sky in 45 days for low-frequency radio waves.

More than 20,000 radio antennas will soon connect over the Internet to scan largely unexplored radio frequencies, hunting for the first stars and galaxies and potentially signals of extraterrestrial intelligence.

The Low Frequency Array (LOFAR) will consist of banks of antennas in 48 stations in the Netherlands and elsewhere in Europe, all hooked up by fiber optic cables. Signals from these stations will be combined using a supercomputer, transforming the array into “perhaps the most complex and versatile radio telescope ever attempted,” said Heino Falcke, chairman of the board for the International LOFAR Telescope.

Currently 16,000 of LOFAR’s antennas and 41 of its stations are up, and the array will be completed by the middle of this year. All told, LOFAR will have a resolution equivalent to a telescope 620 miles (1,000 kilometers) in diameter. In addition, “it’s an expandable design — we can always come along later and add additional stations,” said Michael Wise at ASTRON, the Netherlands Institute for Radio Astronomy.

Since LOFAR is so large, it can scan large parts of the heavens — its first all-sky survey, which started Jan. 9, can sweep across “the entire northern sky twice in just 45 days,” said George Heald of ASTRON.

LOFAR is also very fast, capable of measuring events only five-billionths of a second long. In addition, the fact that LOFAR is essentially many different radio telescopes knit together means it can run, say, three different science projects simultaneously, Wise said.

The array is designed to monitor low-frequency radio waves, a largely unexplored part of radiation from the sky. One critical source of these radio emissions are extremely feeble signals from the cold hydrogen gas that dominated the cosmos during the so-called dark ages of the universe. As stars eventually came into being, they would have left scars on this hydrogen, and by analyzing how the radio signals from this gas changed over time, scientists can therefore learn much about how the first galaxies came to be.

“This is a pivotal phase in the early evolution of the universe, stretching from 400 million to 800 million years after the Big Bang,” said Ger de Bruyn of ASTRON. “We’d like to know when exactly it happened, how it happened, how fast it happened.”

LOFAR will also scan for artificial radio emissions as part of the search for extraterrestrial intelligence (SETI). Past SETI missions focused on higher frequency radio waves, but perhaps alien civilizations preferred lower frequencies.

“LOFAR can do interesting SETI experiments,” Falcke told SPACE.com. “In the next couple of years, we’ll be trying it.”

Low-frequency radio waves are also emitted around intensely powerful cosmic objects such as black holes, and investigating these could help scientists better understand the inner workings of these ferocious systems. For instance, when it comes to pulsars — the highly magnetized and rapidly rotating neutron stars that can form after supernovas — LOFAR can monitor radio emissions from within about 60 miles (100 kilometers) of the pulsar’s surface, said Jason Hessels of ASTRON.

LOFAR will open its capabilities to astronomers internationally starting in May. Scientists at LOFAR detailed their work earlier this month at the 219th annual meeting of the American Astronomical Society in Austin, Texas.

Source:Scientific American

Could Simple Experiments Reveal the Quantum Nature of Spacetime?


Conventional wisdom has it that putting the words “quantum gravity” and “experiment” in the same sentence is like bringing matter into contact with antimatter. All you get is a big explosion; the two just don’t go together. The distinctively quantum features of gravity only show up in extreme settings such as the belly of a black hole or the nascent universe, over distances too small and energies too large to reproduce in any laboratory. Even alien civilizations that command the energy resources of a whole galaxy probably couldn’t do it.

Physicists have never been much for conventional wisdom, though, and the dream of studying quantum gravity is too enthralling to give up. Right now, physicists don’t really know how gravity works—they have quantum theories for every force of nature except this one. And as Einstein showed, gravity is special: it is not just any old force, but a reflection of the structure of spacetime, on which all else depends. In a quantum theory of gravity, all the principles that govern nature will come together. If physicists can observe some distinctively quantum feature of gravity, they will have glimpsed the underlying unity of the natural world.

Even if they can’t crank up their particle accelerators to the requisite energies, that hasn’t stopped them from devising indirect experiments—experiments that don’t try to swallow the whole problem in one gulp, but nibble at it. My award-winning colleague Michael Moyer describes one in February’s cover story, and lots of others are burbling, too. Rather than matter and antimatter, “quantum gravity” and “experiment” are more like peanut butter and chocolate. They actually go together quite tastily.

An example came out at the American Astronomical Society meeting in Austin last month. Robert Nemiroff of Michigan Technological University presented his team’s study of extremely high-energy, short-wavelength cosmic gamma rays. The idea, which goes back to the late 1990s, is that short-wavelength photons may be more sensitive to the microscopic quantum structure of spacetime than long-wavelength ones, just as a car with small tires rattles with road bumps that a monster truck doesn’t even feel. The effect might be slight, but if the photons travel for billions of years, even the minutest slowdown or speed-up can appreciably change their time of arrival. Nemiroff’s team focused on gamma-ray burst GRB 090510A, observed by the Fermi space telescope. It went off about 7 billion years ago, and photons of short and long wavelength arrived at almost the same time—no more than about 1 millisecond apart. Any speed difference was at most one part in 1020, implying that quantum gravity hardly waylaid these photons at all.

Theoretical physicists have long debated whether quantum gravity would alter photon speed, and most were not surprised by the negative result. But what’s important is the change of mindset. Experimenters and observers care less about what we should see than what we can see. These are people who love to build stuff. If they can build some gizmo that might bring gravity and quantum mechanics into contact, they’ll do it, whatever the theorists might say. They take an “if you build it, something will come” attitude. Historically, physics has been well-served by going out to look at nature with a minimum of prejudice.

The latest brainstorm is to apply techniques from quantum optics and related disciplines, which manipulate photons and other particles in order to build encrypted communications links, develop the components of a quantum computer, and study matter at extremely low temperatures. The tool of this trade is an interferometer, an apparatus that probes the wave nature of particles. It consists of a particle source, a particle detector, and two paths to get from one to the other. Being quantum, a particle goes both ways. That is to say, the wave corresponding to the particle splits in two, travels the distance, and fuses back together again. The relative length of the paths (or anything else that differentiates them) determines whether the waves will mutually reinforce or cancel and therefore what the detector will detect.

At first glance, these setups are the last place you’d go to look for quantum gravity. They are decidedly low-energy experiments, usually conducted on lab benches the size of dining-room tables. There is nary a gamma ray or accelerated particle to be found. But Moyer’s cover story describes how an interferometer can serve as an extremely precise ranging instrument. Any change in the paths’ relative lengths, as you might expect if spacetime is roiled by quantum fluctuations, will register at the detector.

Last spring, a team of physicists in Vienna led by Časlav Brukner explored another use of interferometers: to see whether quantum particles truly obey gravity as Einstein conceived it. This isn’t quantum gravity, per se—the particles are quantum, but gravity behaves in a strictly classical way. Nonetheless, it is a fascinating case of how the two theories interact. You might think that the gravity on a single particle is way too feeble to measure, but an interferometer can manage it. You set it up so that the two paths are at different heights and therefore experience a different gravitational potential, which registers at the detector.

This type of experiment, first done in 1975 using neutrons, confirms that Newton’s law of gravitation applies equally to planets and particles. Later experiments, notably by Steven Chu, Nobel laureate and U.S. Secretary of Energy, aimed to go a step farther and hunt for distinctive features of general relativity, beyond those of Newton’s theory. They claimed to find them, but others were wary. Ironically, Chu’s leading skeptic was none other than a fellow recipient of the 1997 Nobel, Claude Cohen-Tannoudji.

The Vienna team bypassed the controversy by proposing a modified experiment. It would send not just any particle through the interferometer, but one that acts like a miniature clock—marking time by rotating or decaying. General relativity predicts that clocks run slower the deeper they get into a gravitational field, which, in this experiment, would do more than differentiate two paths of unequal height; it would wash away the wave nature of the particle altogether. The fading-away of the wave properties would be the unmistakable fingerprint of general relativity and a stepping-stone to quantum gravity. Current interferometers lack the necessary precision to look for this effect, but it is just a matter of time. (Sorry, couldn’t resist.) For more, see the authors’ own blog post and their paper in Nature Communications last fall.

Yet another approach builds on efforts to see distinctive quantum effects in systems of ever increasing size. The Viennese physicists, working with a colleague in London, reasoned that there are two ways to achieve high energy and therefore probe quantum gravity. You can either pack a lot of energy into a single particle or you can assemble a huge number of low-energy particles and coax them into behaving collectively like one big particle.

The proposed experiment involves a tiny mirror on a tiny spring. By shining light on the mirror, you damp it down until the contraption reaches its minimum possible energy, at which point it acts like a single quantum. With a mass of 20 micrograms, it would have as much total energy (via E=mc2) as the most powerful lone particle imaginable. By continuing to shine light on the mirror, you have complete control over its position and momentum. The team suggests running the device through a cycle: reposition it slightly, then give it a velocity, then return it to its original position, then bring it to a stop. Even though the mirror is back where it started, it is not exactly the same as it was before—the quantum wave corresponding to the mirror has shifted slightly. By analogy, when a car engine goes through a cycle, it returns to its same internal state, but leaves you farther down the road.

Technically, the residual shift is a consequence of quantum noncommutativity—the fact that the order of operations makes a difference to a quantum system. Repositioning, then changing velocity, is not the same as changing velocity, then repositioning. Noncommutativity underpins the famous Heisenberg uncertainty principle, whereby you can’t measure both the position and momentum of something with perfect precision; you need to make a tradeoff.

What makes this interesting is that quantum gravity could modify the uncertainty principle. As Sabine Hossenfelder at Backreaction described last Wednesday, gravitational effects may set a minimum length that anything in nature could ever have, which means that no matter how much momentum imprecision you’re willing to accept, a position measurement could never be more precise than the minimum length. The mini-mirror experiment would pick that up.

Still another approach suggested by the ever-inventive Viennese, which hasn’t lent itself to a specific experiment yet, but is generally inspired by the experimentalist mindset, is to define quantum gravitational ideas in concrete rather than abstract terms. Theorists think that quantum fluctuations in spacetime might make cause-effect sequences ambiguous, with the practical consequence of changing the types of correlations physicists observe in the lab. But the Viennese suggest thinking about it the other way round: Physicists observe certain types of correlations in the lab and, from these, draw conclusions about spacetime.

The nice thing about this inversion is that you can imagine observing correlations that aren’t explicable in spatiotemporal terms—for instance, correlations that can’t be placed in a causal sequence, not even in principle. Per the usual style of quantum information theorists, the team expresses its idea in the form of a game. Suppose two players, Alice and Bob, are in two booths, each equipped with a red and a green button and a red and a green light; when Alice presses a button, the corresponding light comes on in Bob’s booth, and vice versa.

Each player flips a coin. The object of the game: to guess the outcome of the other person’s coin toss. They have to make their guesses before they flip their coins. In normal spacetime, the game unfolds in a causal sequence. One of the players has to go first—say, Alice. Her red and green lights are dark, since Bob hasn’t had a chance to press any button yet, so the best she can do is guess his outcome. She sends her own outcome to Bob, so that at least he always gets the right answer. Overall, they get both outcomes correct 75% of the time.

But imagine that the button and light are correlated independently of who goes first. Then, Alice’s light does go on and she can make an educated guess about Bob’s outcome. If you extend quantum mechanics to cover this situation, you can calculate the odds of winning: about 85%, better than they could achieve when everything is neatly ordered.

When quantum effects enter into play, “spacetime” loses some of the most basic features we associate with it, such as the notion that objects reside in certain places at certain times. In the Viennese scenario, you lose the ability to tell a story: one thing happened, then another, then another. It becomes a Dadaist jumble. That is such a bizarre and abstract concept, even for theoretical physicists, that any way to visualize it counts as progress. So even when experimenters can’t build actual experiments, their feet-on-the-ground mentality provides a fresh look at some of the hardest problems in modern science.

Source:Scientific American